133 related articles for article (PubMed ID: 7642467)
1. Modulators of multidrug resistance. Preclinical studies.
Ford JM
Hematol Oncol Clin North Am; 1995 Apr; 9(2):337-61. PubMed ID: 7642467
[TBL] [Abstract][Full Text] [Related]
2. P-glycoprotein-mediated multidrug resistance: experimental and clinical strategies for its reversal.
Ford JM; Yang JM; Hait WN
Cancer Treat Res; 1996; 87():3-38. PubMed ID: 8886447
[TBL] [Abstract][Full Text] [Related]
3. Clinical studies with modulators of multidrug resistance.
Fisher GA; Sikic BI
Hematol Oncol Clin North Am; 1995 Apr; 9(2):363-82. PubMed ID: 7642468
[TBL] [Abstract][Full Text] [Related]
4. Multidrug resistance in pediatric malignancies.
Chan HS; DeBoer G; Haddad G; Gallie BL; Ling V
Hematol Oncol Clin North Am; 1995 Apr; 9(2):275-318. PubMed ID: 7642465
[TBL] [Abstract][Full Text] [Related]
5. [Reversal of acquired resistance to vinca alkaloids and anthracycline antibiotics by calcium channel blockers and calmodulin inhibitors].
Tsuruo T
Gan To Kagaku Ryoho; 1984 Mar; 11(3 Pt 2):750-9. PubMed ID: 6585181
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effect of steroidal alkaloids on drug transport and multidrug resistance in human cancer cells.
Lavie Y; Harel-Orbital T; Gaffield W; Liscovitch M
Anticancer Res; 2001; 21(2A):1189-94. PubMed ID: 11396162
[TBL] [Abstract][Full Text] [Related]
7. Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models.
Peer D; Dekel Y; Melikhov D; Margalit R
Cancer Res; 2004 Oct; 64(20):7562-9. PubMed ID: 15492283
[TBL] [Abstract][Full Text] [Related]
8. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
Chen LM; Liang YJ; Ruan JW; Ding Y; Wang XW; Shi Z; Gu LQ; Yang XP; Fu LW
J Pharm Pharmacol; 2004 Aug; 56(8):1061-6. PubMed ID: 15285852
[TBL] [Abstract][Full Text] [Related]
9. MDR expression in normal tissues. Pharmacologic implications for the clinical use of P-glycoprotein inhibitors.
Lum BL; Gosland MP
Hematol Oncol Clin North Am; 1995 Apr; 9(2):319-36. PubMed ID: 7642466
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in P-glycoprotein-mediated multidrug resistance reversal mechanisms.
Li X; Li JP; Yuan HY; Gao X; Qu XJ; Xu WF; Tang W
Methods Find Exp Clin Pharmacol; 2007 Nov; 29(9):607-17. PubMed ID: 18193112
[TBL] [Abstract][Full Text] [Related]
11. Molecular targets in oncology: implications of the multidrug resistance gene.
Lum BL; Gosland MP; Kaubisch S; Sikic BI
Pharmacotherapy; 1993; 13(2):88-109. PubMed ID: 8097038
[TBL] [Abstract][Full Text] [Related]
12. Multidrug resistance mediated by P-glycoprotein in haematological malignancies.
Pasman PC; Schouten HC
Neth J Med; 1993 Jun; 42(5-6):218-31. PubMed ID: 8104318
[TBL] [Abstract][Full Text] [Related]
13. Multidrug resistance: clinical relevance in solid tumours and strategies for circumvention.
Kaye SB
Curr Opin Oncol; 1998 Aug; 10 Suppl 1():S15-9. PubMed ID: 9801854
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo characterizations of tetrandrine on the reversal of P-glycoprotein-mediated drug resistance to paclitaxel.
Zhu X; Sui M; Fan W
Anticancer Res; 2005; 25(3B):1953-62. PubMed ID: 16158930
[TBL] [Abstract][Full Text] [Related]
15. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance.
Newman MJ; Rodarte JC; Benbatoul KD; Romano SJ; Zhang C; Krane S; Moran EJ; Uyeda RT; Dixon R; Guns ES; Mayer LD
Cancer Res; 2000 Jun; 60(11):2964-72. PubMed ID: 10850444
[TBL] [Abstract][Full Text] [Related]
16. A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier.
Hendrikse NH; de Vries EG; Eriks-Fluks L; van der Graaf WT; Hospers GA; Willemsen AT; Vaalburg W; Franssen EJ
Cancer Res; 1999 May; 59(10):2411-6. PubMed ID: 10344751
[TBL] [Abstract][Full Text] [Related]
17. The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: studies of the Southwest Oncology Group Leukemia Research Program.
Willman CL
Semin Hematol; 1997 Oct; 34(4 Suppl 5):25-33. PubMed ID: 9408958
[TBL] [Abstract][Full Text] [Related]
18. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
19. Drug resistance in chemotherapy for breast cancer.
Saeki T; Tsuruo T; Sato W; Nishikawsa K
Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():84-9. PubMed ID: 16273361
[TBL] [Abstract][Full Text] [Related]
20. Reversal of drug resistance in P-glycoprotein-expressing T-cell acute lymphoblastic CEM leukemia cells by copper N-(2-hydroxy acetophenone) glycinate and oxalyl bis (N-phenyl) hydroxamic acid.
Majumder S; Dutta P; Mukherjee P; Datta ER; Efferth T; Bhattacharya S; Choudhuri SK
Cancer Lett; 2006 Nov; 244(1):16-23. PubMed ID: 16410038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]